Tocilizumab
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
TAKAYASU ARTERITIS
Conditions
TAKAYASU ARTERITIS
Trial Timeline
Jun 10, 2014 → Feb 1, 2019
NCT ID
NCT02101333About Tocilizumab
Tocilizumab is a phase 3 stage product being developed by Chugai Pharmaceutical for TAKAYASU ARTERITIS. The current trial status is completed. This product is registered under clinical trial identifier NCT02101333. Target conditions include TAKAYASU ARTERITIS.
What happened to similar drugs?
0 of 1 similar drugs in TAKAYASU ARTERITIS were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02101333 | Phase 3 | Completed |
Competing Products
1 competing product in TAKAYASU ARTERITIS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Upadacitinib + Placebo for Upadacitinib + Prednisolone | AbbVie | Phase 3 | 44 |